| 12/12/2024 | BKIG | Moody’s turns Bristol view to stable
|
| 2/16/2024 | IG | Market Commentary: Heavy high-grade bond supply eyed in short holiday week; energy space strong
|
| 2/15/2024 | IG | New Issue: Bristol-Myers Squibb details $13 billion of notes in nine-part offer
|
| 2/14/2024 | IG | Bristol-Myers Squibb prices $13 billion of notes in nine-part offer
|
| 2/14/2024 | BKIG | Moody’s gives Bristol-Myers notes A2
|
| 2/14/2024 | BKIG | S&P assigns A to Bristol-Myers notes
|
| 2/13/2024 | IG | Bristol-Myers Squibb to price notes offering in eight tranches
|
| 2/12/2024 | BKIG | Moody’s views Bristol-Myers negatively
|
| 2/9/2024 | IG | Market Commentary: Busy high-grade corporate deal pace continues; M&A-related supply increases; flows up
|
| 12/22/2023 | BKIG | Moody’s reviews Bristol-Myers for trim
|
| 12/22/2023 | BKIG | Bristol-Myers Squibb to take on new debt for $14 billion Karuna buy
|
| 10/30/2023 | IG | New Issue: Bristol-Myers Squibb sells $4.5 billion of senior notes in four parts
|
| 10/30/2023 | BKIG | S&P assigns A+ to Bristol-Myers notes
|
| 10/30/2023 | BKIG | Moody’s gives Bristol-Myers notes A2
|
| 10/30/2023 | IG | Bristol-Myers Squibb to price notes offering in four tranches
|
| 3/2/2022 | IGLM | Bristol-Myers details early tender amounts and pricing, tweaks offer
|
| 3/2/2022 | IGLM | Bristol-Myers Squibb details early tender amounts, tweaks offer
|
| 2/22/2022 | BKIG | S&P turns Bristol-Myers view to stable
|
| 2/15/2022 | IG | New Issue: Bristol-Myers Squibb sells $6 billion of senior notes in four parts
|
| 2/15/2022 | BKIG | S&P rates Bristol-Myers Squibb notes A+
|
| 2/15/2022 | BKIG | Moody's gives A2 to Bristol-Myers notes
|
| 2/15/2022 | IGLM | Bristol-Myers Squibb to buy notes from 22 series for up to $4 billion
|
| 2/15/2022 | IG | Bristol-Myers Squibb to price notes offering in four tranches
|
| 2/22/2021 | IGLM | Bristol-Myers, Celgene to redeem 4% notes, 3.25% notes due 2023
|
| 2/19/2021 | IGLM | Bristol-Myers Squibb announces pricing on tender offers for 20 series
|
| 2/19/2021 | IGLM | Bristol-Myers Squibb gives early results of tender offers for 20 series
|
| 2/4/2021 | BKIG | Moody’s shifts Bristol-Myers view to stable
|
| 2/4/2021 | BWIGLM | Bristol-Myers starts leverage reduction goal with $4 billion tender
|
| 2/4/2021 | IGLM | Bristol-Myers Squibb kicks off $4 billion tender offers for 20 series
|
| 11/12/2020 | BKIG | Fitch rates Bristol-Myers notes
|
| 11/10/2020 | IG | Market Commentary: L3Harris, Rexford, Verizon, Standard Chartered, Allianz in primary; credit spreads ease
|
| 11/10/2020 | IG | New Issue: Bristol-Myers Squibb details $7 billion of fixed-rate senior notes in six tranches
|
| 11/10/2020 | IG | Market Commentary: Morning Commentary: Verizon to sell five tranches; Standard Chartered, others on deck
|
| 11/9/2020 | IG | Market Commentary: Bristol-Myers, Republic Services, Vereit, ConEd, Entergy, Ameren price; credit spreads firm
|
| 11/9/2020 | IG | New Issue: Bristol-Myers Squibb sells $7 billion of fixed-rate senior notes in six tranches
|
| 11/9/2020 | BKIG | S&P gives Bristol-Myers notes A+
|
| 11/9/2020 | BKIG | Moody’s assigns Bristol-Myers notes A2
|
| 11/9/2020 | IG | Market Commentary: Morning Commentary: High-grade supply resumes; Bristol-Myers, Vereit, Entergy on tap
|
| 11/9/2020 | IG | Bristol-Myers Squibb offers floaters, six series of fixed-rate notes
|
| 10/5/2020 | IG | Market Commentary: Berkshire Hathaway, PepsiCo, Everest Reinsurance, Leidos, WEC Energy, Swedish Export price
|
| 10/5/2020 | BKBWIG | Bristol-Myers Squibb plans debt for $13.1 billion MyoKardia purchase
|
| 10/5/2020 | BKCVIG | S&P shifts Bristol-Myers view to negative
|
| 5/7/2020 | BKBWIG | Bristol-Myers Squibb now on track for 1.5x leverage by year-end 2023
|
| 1/9/2020 | BKBWIG | Bristol-Myers Squibb expects to get leverage to 1.5x by year-end 2022
|
| 12/31/2019 | IG | Outlook 2020: High-grade bond spreads mostly expected to improve; bank paper to grind tighter
|
| 12/24/2019 | IG | Market Commentary: High-grade primary market shuts down ahead of holidays; Charter tightens; AbbVie steady
|
| 12/18/2019 | IG | Market Commentary: High-grade corporate bond supply winds down for year; FHLBank on tap; AbbVie firms
|
| 12/11/2019 | IG | Market Commentary: Sterling Bancorp offers fixed/floaters; Steel Dynamics firms; AbbVie, Bristol-Myers tight
|
| 11/25/2019 | BKIG | Fitch shifts Bristol-Myers view to negative
|
| 11/21/2019 | BKIG | S&P boosts Celgene, off watch
|
| 11/21/2019 | IGLM | Bristol-Myers announces results of exchange offers for Celgene notes
|
| 11/15/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
| 11/12/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
| 11/7/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
| 11/5/2019 | IGLM | Bristol-Myers Squibb again extends exchange offers for Celgene notes
|
| 11/1/2019 | IGLM | Bristol-Myers Squibb again extends exchange offers for Celgene notes
|
| 10/30/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
| 10/18/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
| 10/8/2019 | IGLM | Bristol-Myers Squibb extends exchange offers for Celgene notes
|
| 9/23/2019 | IGLM | Bristol-Myers Squibb again extends exchange offers for Celgene notes
|
| 8/26/2019 | IGLM | Bristol-Myers Squibb to pay down debt with divestiture proceeds
|
| 6/28/2019 | IGLM | Bristol-Myers extends exchange offers for Celgene notes
|
| 6/6/2019 | IG | Market Commentary: Supply slows; Camden, TTX, Apollo, Inter-American Development Bank, FHLB price; inflows return
|
| 6/3/2019 | IG | Market Commentary: Home Depot, Public Service, Dayton Power, Wintrust price; CDP, Parker-Hannifin eye new issues
|
| 5/29/2019 | IG | Market Commentary: High-grade supply quiet; Dollar Tree eases, Dollar General flat ahead of earnings reports
|
| 5/28/2019 | IG | Market Commentary: MasterCard, San Diego Gas, Southwest Gas among issuers; Unibail-Rodamco-Westfield eyes deal
|
| 5/28/2019 | IG | Market Commentary: Morning Commentary: MasterCard, San Diego Gas, Southwest Gas on tap; light supply eyed
|
| 5/24/2019 | IGLM | Bristol-Myers extends exchange offers for Celgene notes
|
| 5/17/2019 | IG | Market Commentary: High-grade action quiet; steady volume on tap ahead of holiday; inflows dip; Fidelity firms
|
| 5/13/2019 | IG | Market Commentary: Nordic Investment Bank offers $1 billion; Nstar, Fidelity, Avangrid eyed; credit spreads ease
|
| 5/13/2019 | IG | Market Commentary: Morning Commentary: Nstar Electric plans green bonds; Fidelity, Avangrid deals eyed
|
| 5/10/2019 | IG | Market Commentary: High-grade supply quiet; Fidelity, Avangrid, Nstar deals eyed; IBM eases; Bristol-Myers firms
|
| 5/9/2019 | IG | Market Commentary: Motorola, O’Reilly tap primary market; high-grade inflows rise; week’s deal volume strong
|
| 5/9/2019 | IG | Market Commentary: Morning Commentary: High-grade supply robust; O’Reilly Automotive, Motorola offer notes
|
| 5/8/2019 | IG | Market Commentary: IBM prices $20 billion; Bell Canada, Reinsurance, AvalonBay, Honda, EIB among issuers
|
| 5/8/2019 | IG | Market Commentary: Morning Commentary: IBM, AvalonBay, Reinsurance Group, Bell Canada, EIB offer notes
|
| 5/8/2019 | IG | New Issue: Bristol-Myers prices $19 billion of senior notes in nine tranches
|
| 5/7/2019 | IG | Market Commentary: Principal Financial, Brixmor tap primary market; Bristol-Myers, Fidelity, T-Mobile deals eyed
|
| 5/7/2019 | IG | Market Commentary: Morning Commentary: Principal Financial, Brixmor on deck; heavy bond deal pipeline eyed
|
| 5/6/2019 | IG | Market Commentary: Utilities American Water, Public Service, ConEd tap primary market; M&A funding deals eyed
|
| 5/6/2019 | IG | Market Commentary: Morning Commentary: American Water, PSE&G, ConEd offer bonds; M&A funding deals eyed
|
| 5/3/2019 | IG | Market Commentary: Paccar Financial, Pacific Premier Bancorp price; heavy volume eyed; Starbucks softens
|
| 5/3/2019 | BKIG | Fitch rates Bristol-Myers notes A-
|
| 5/3/2019 | IG | Market Commentary: Morning Commentary: Pacific Premier Bancorp on tap; inflows down; Starbucks softens
|
| 5/2/2019 | IG | Market Commentary: Starbucks, RBS, Eni, Florida Light in primary market; inflows decline; Bristol-Myers eyed
|
| 5/2/2019 | IG | Maturities set in Bristol-Myers’ eight-part offering of dollar notes
|
| 5/2/2019 | BKCVIG | S&P rates Bristol-Myers notes A+
|
| 5/2/2019 | IGLM | Bristol-Myers gives early results of offers for Celgene notes
|
| 5/2/2019 | IG | Market Commentary: Morning Commentary: Starbucks, RBS, Florida Power to price; Bristol-Myers offering eyed
|
| 5/1/2019 | IG | Market Commentary: CNA Financial prices notes; T-Mobile, Bristol-Myers Squibb, Fidelity National eye deals
|
| 5/1/2019 | IG | Bristol-Myers sets investor calls for eight-part offering of notes
|
| 4/29/2019 | IG | Market Commentary: Norfolk, Lear, Celanese, AEP, Fannie Mae among high-grade issuers; Bristol-Myers eyed
|
| 4/29/2019 | IG | Market Commentary: Morning Commentary: Lear, Philip Morris, Norfolk Southern, Celanese notes on tap
|
| 4/25/2019 | IG | Market Commentary: Omers taps primary; Bristol-Myers Squibb deal on horizon; corporate inflows jump; Walmart soft
|
| 4/25/2019 | IG | Bristol-Myers’ $10 billion-$15 billion bond deal on the horizon to fund Celgene merger
|
| 4/17/2019 | BKCVIG | S&P rates Bristol-Myers notes A+
|
| 4/17/2019 | IGLM | Bristol-Myers Squibb launches exchange offer for 19 Celgene notes
|
| 1/7/2019 | CVIG | Fitch puts Bristol-Myers on watch
|
| 1/3/2019 | CVIG | Moody's may lower Bristol-Myers
|
| 6/5/2018 | BKCVIG | Fitch affirms Bristol-Myers
|
| 2/7/2018 | BKCVIG | Moody’s changes Bristol-Myers to stable
|
| 6/21/2017 | IGLM | Bristol-Myers Squibb gets tenders for $337 million of three series
|
| 6/20/2017 | IGLM | Bristol-Myers prices tender offer for 5.875%, 6.125%, 6.875% debt
|
| 6/14/2017 | IGLM | Bristol-Myers tenders for 5.875% and 6.125% notes, 6.875% debentures
|
| 2/27/2017 | IG | Market Commentary: Morning Commentary: Westpac, Moody’s, ConEd, Charles Schwab prep deals; Bristol-Myers softens
|
| 2/24/2017 | IG | Market Commentary: Fannie Mae, Pfizer sell notes; Bristol-Myers steady; Mizuho, Parker-Hannifin tighten
|
| 2/24/2017 | IG | Market Commentary: Morning Commentary: Pfizer markets 30-year notes; Bristol-Myers improves in secondary market
|
| 2/23/2017 | IG | Market Commentary: Danske, Nederlandse Waterschapsbank price; Fannie Mae offers notes; Bristol-Myers steady
|
| 2/23/2017 | IG | Market Commentary: Morning Commentary: Fannie Mae offers notes; Quebec preps bond deal; Bristol-Myers better
|
| 2/22/2017 | IG | Market Commentary: Mizuho, Bristol-Myers, Paccar, Spire tap high-grade primary market; LyondellBasell improves
|
| 2/22/2017 | IG | New Issue: Bristol-Myers Squibb prices $1.5 billion of two-year, 10-year notes
|
| 2/22/2017 | CVIG | Fitch: Bristol-Myers notes A-
|
| 2/22/2017 | CVIG | Moody’s gives Bristol-Myers notes A2
|
| 2/22/2017 | CVIG | S&P: Bristol-Myers notes A+
|
| 2/22/2017 | IG | Market Commentary: Morning Commentary: Bristol-Myers, Mizuho, Spire offer high-grade bonds; LyondellBasell firms
|
| 2/22/2017 | IG | Bristol-Myers to sell two-year, 10-year notes via five bookrunners
|
| 2/13/2017 | CVIG | Moody’s: Bristol-Myers view to negative
|
| 5/27/2015 | IGLM | Bristol-Myers wraps oversubscribed tender offer for $500 million notes
|
| 5/12/2015 | IGLM | Bristol-Myers increases tender to $500 million, gives early results
|
| 4/30/2015 | CVIG | Fitch: Bristol-Myers bond A-
|
| 4/29/2015 | CVIG | S&P: Bistol-Meyers notes A+
|
| 4/29/2015 | CVIG | Moody’s rates Bristol-Myers notes A2
|
| 4/28/2015 | IGLM | Bristol-Myers tenders for up to $400 million of four series of notes
|
| 12/11/2014 | CVIG | Fitch lifts Bristol-Myers view to stable
|
| 1/31/2014 | IGLM | Bristol-Myers to redeem $582.06 million 5.45% notes due 2018
|
| 12/23/2013 | CVIG | Fitch: Bristol-Myers view negative
|
| 10/25/2013 | IG | Market Commentary: No slowdown in sight for high-grade primary; Bristol-Myers notes flat; ABN slightly wider
|
| 10/24/2013 | CVIG | Moody's gives Bristol-Myers notes A2
|
| 10/24/2013 | CVIG | S&P: Bristol-Myers notes A+
|
| 10/24/2013 | IG | Bristol-Myers eyeing three-part offering due in 2019, 2023 and 2044
|
| 10/24/2013 | IG | New Issue: Bristol-Myers sells $1.5 billion senior notes due in 2019, 2023, 2044
|
| 10/24/2013 | IG | Market Commentary: Bristol-Myers, Bank of Nova Scotia, Prologis price as strong tone continues; ABN Amro firms
|
| 9/23/2013 | CVIG | Moody's: Bristol-Myers view negative
|
| 7/1/2013 | CVIG | Fitch cuts Bristol-Myers to A-
|
| 7/26/2012 | CVIG | Moody's rates Bristol-Myers Squibb notes A2
|
| 7/26/2012 | CVIGPF | Bristol-Myers Squibb files automatic shelf for stock, preferreds, debt
|
| 7/26/2012 | CVIGPF | S&P: Bristol-Myers Squibb notes A+, preferreds A-
|
| 7/26/2012 | IG | New Issue: Bristol-Myers sells $2 billion of five-, 10-, 30-year bonds
|
| 7/26/2012 | IG | Market Commentary: Bristol-Myers brings deal for M&A; Australian financials price; bank paper spreads tighten
|
| 7/3/2012 | BKCVIG | Fitch cuts Bristol Myers Squibb
|
| 7/2/2012 | CVIG | Moody's affirms Bristol-Myers
|
| 5/31/2012 | BKCVIG | S&P lifts health companies
|
| 1/11/2012 | CVIG | Fitch: Bristol-Myers unchanged
|
| 1/9/2012 | CVIG | Moody's: Bristol-Myers unaffected by acquisition
|
| 1/9/2012 | CVIG | S&P: Bristol-Myers unaffected
|
| 11/22/2011 | CVIG | Moody's: Bristol-Myers loan A2
|
| 7/25/2011 | CVIG | Fitch affirms Bristol-Myers
|
| 12/3/2010 | IGLM | Bristol-Myers records $1.09 billion tenders in oversubscribed offer
|
| 11/18/2010 | IGLM | Bristol-Myers Squibb sets tender offer prices for 6.125%, 5.875% notes
|
| 11/17/2010 | IGLM | Bristol-Myers Squibb gets tenders for $1.09 billion of notes so far
|
| 11/3/2010 | IGLM | Bristol-Myers Squibb tenders for $750 million of four note series
|
| 8/27/2010 | CVIG | Fitch: Bristol-Myers Squibb outlook negative
|
| 11/16/2009 | CVIG | Fitch: Bristol-Myers unchanged
|
| 11/16/2009 | CVIG | Moody's: Bristol-Myers unchanged
|
| 8/27/2009 | IG | Fitch affirms Bristol-Myers
|
| 8/3/2009 | IG | Moody's lifts Bristol-Myers outlook to stable
|
| 9/12/2008 | CVIG | Fitch affirms Bristol-Myers Squibb
|
| 7/31/2008 | CVIG | Moody's: Bristol-Myers view negative
|
| 5/15/2008 | IG | Market Commentary: Eaton, NiSource, Deutsche Bank, Harley Davidson, HBOS price; new issue premiums continue decrease
|
| 4/29/2008 | IG | Market Commentary: Bank of America, Fifth Third, Pearson, KLA-Tencor price ahead of Fed; flat tone seen as positive
|
| 4/28/2008 | IG | Market Commentary: Bristol-Myers Squibb, AMB Property price; Fifth Third, KLA-Tencor announce upcoming issues
|
| 4/28/2008 | CVIG | S&P assigns Bristol-Myers notes A+
|
| 4/28/2008 | CVIG | Moody's gives Bristol-Myers notes A2
|
| 4/28/2008 | CVIG | Fitch rates Bristol-Myers notes A+
|
| 4/28/2008 | CVIG | Bristol-Myers Squibb files automatic shelf registration
|
| 4/28/2008 | IG | New Issue: Bristol-Myers Squibb prices $1.6 billion in 10-, 30-year notes
|
